ReviewCurrent opinion in infectious diseases2009
Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community.
Review in Current opinion in infectious diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02508610 (DNA Sequencing of MDR TB in Eastern Siberia), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DNA Sequencing of MDR TB in Eastern Siberia
Who cites it
31 citing papers in PubMed.
- Prevalence of drug resistant tuberculosis and its associated factors among tuberculosis patients at wolkite health center in central Ethiopia.Scientific reports · 2026Article
- Overcoming Treatment Challenges in HIV-Associated Mycobacterial Diseases: New Therapeutic Frontiers.International journal of molecular sciences · 2025Review
- New volatile organic compounds from the exhaled breath of active tuberculosis patients.Scientific reports · 2025Article
- High rates of culture conversion and low loss to follow-up in MDR-TB patients managed at Regional Referral Hospitals in Uganda.BMC infectious diseases · 2021Article
- Article
- Metformin as Host-Directed Therapy for TB Treatment: Scoping Review.Frontiers in microbiology · 2020Article
- Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis.Antimicrobial agents and chemotherapy · 2018Article
- Tuberculosis Burden in Ethiopia from 1990 to 2016: Evidence from the Global Burden of Diseases 2016 Study.Ethiopian journal of health sciences · 2018Article
- Protein tyrosine kinase, PtkA, is required for Mycobacterium tuberculosis growth in macrophages.Scientific reports · 2018Article
- Ureidopyrazine Derivatives: Synthesis and Biological Evaluation as Anti-Infectives and Abiotic Elicitors.Molecules (Basel, Switzerland) · 2017Article
- Diabetes-related tuberculosis in the Middle East: an urgent need for regional research.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2015Review
- Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014.Tuberculosis and respiratory diseases · 2015Article
- Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.PloS one · 2015Article
- Article
- Inhibition of glutamine synthetase: a potential drug target in Mycobacterium tuberculosis.Molecules (Basel, Switzerland) · 2014Review
- Understanding pharmacokinetics to improve tuberculosis treatment outcome.Expert opinion on drug metabolism & toxicology · 2014Review
- Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.Antimicrobial agents and chemotherapy · 2014Article
- Drug-resistant tuberculosis: pediatric guidelines.Current infectious disease reports · 2013Article
- Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.PloS one · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewPhysicians, researchers and policy makers must understand the myriad consequences of multidrug and extensively drug-resistant tuberculosis (TB) within the HIV community in order to guide clinical care, research and resource allocation. RECENT
findingsExtensively drug-resistant TB can no longer be considered as occurring in isolated outbreaks as it has been reported in 45 countries from all regions of the world. HIV has been associated as an independent risk factor for infection with drug-resistant TB. HIV patients appear more likely to suffer from primary, transmitted resistance as opposed to developing acquired resistance during the course of treatment for TB. New rapid diagnostics offer promise of providing clinically useful first-line drug susceptibility information but require validation in HIV patients and smear negative individuals. Demonstration projects of community-based treatment of drug-resistant TB and integration of TB and HIV care provide opportunities to decentralize management of drug-resistant TB. SUMMARY: Multidrug-resistant and extensively drug-resistant TB disproportionately affect HIV patients and result in increased morbidity and mortality. In this study, we address these challenging issues and offer some short-term and longer term strategies for their alleviation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.